Breaking News Instant updates and real-time market news.

AAPL

Apple

$160.86

-0.64 (-0.40%)

, SNAP

Snap

$15.13

-0.14 (-0.92%)

07:35
09/13/17
09/13
07:35
09/13/17
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Tuesday in Apple (AAPL), Snap Inc. (SNAP), Teva (TEVA), Pfizer (PFE), Coca Cola (KO), Workday (WDAY), Constellation Brands (STZ), and TD Ameritrade (AMTD).

AAPL

Apple

$160.86

-0.64 (-0.40%)

SNAP

Snap

$15.13

-0.14 (-0.92%)

TEVA

Teva

$19.33

0.83 (4.49%)

PFE

Pfizer

$35.37

1.05 (3.06%)

KO

Coca-Cola

$46.72

0.2 (0.43%)

WDAY

Workday

$106.98

-1.29 (-1.19%)

STZ

Constellation Brands, also tag STZ.B

$204.62

0.92 (0.45%)

AMTD

TD Ameritrade

$44.25

0.54 (1.24%)

  • 13

    Sep

  • 13

    Sep

  • 13

    Sep

  • 13

    Sep

  • 13

    Sep

  • 19

    Sep

  • 25

    Sep

  • 27

    Sep

  • 05

    Oct

  • 17

    Oct

  • 16

    Nov

AAPL Apple
$160.86

-0.64 (-0.40%)

09/13/17
KEYB
09/13/17
NO CHANGE
KEYB
Sector Weight
Apple iPhone X 'disappointing,' says KeyBanc
KeyBanc analyst Andy Hargreaves views Apple iPhone X launch event as largely neutral. The analyst was positively surprised by the Apple Watch functionality and the price increase on the iPhone 8 and 8 Plus, but was disappointed by the lack of incremental functionality in the iPhone X to justify the $999 price point. Hargreaves believes this raises the risk that future cycles will see trade-down behavior and correlated pricing pressure. He reiterates a Sector Weight rating on the shares.
09/13/17
UBSW
09/13/17
NO CHANGE
Target $180
UBSW
Buy
Apple shares reacting in-line with historical norm, says UBS
UBS analyst Steven Milunovich said Apple shares are performing in-line with the stock's history after the company conducted its product launch presentation - down into the event and up or down a bit the day of the event. Historically, what happens next is the stock will be down for a few weeks before moving up heading into earnings. The analyst admitted there were few surprises but the event was still impressive and he said the product pricing, which he views as pushing the envelope, was higher than he expected. Milunovich reiterated his Buy rating and $180 price target on Apple shares.
09/13/17
KEYB
09/13/17
NO CHANGE
KEYB
Apple new iPhone 8/X launch largely in-line with expectations, says KeyBanc
KeyBanc analyst John Vinh says that the incremental features and enhancements associated with the new Apple (AAPL) iPhones announced are largely in-line with expectations. The analyst points out that Apple announced three new phones, with key features including facial identification, removal of the home button on the iPhone X, wireless charging, and fast charging. Vihn sees the new phone launch as most positive for Broadcom (AVGO), Cypress Semiconductor (CY), Integrated Device (IDTI), and Skyworks (SWKS).
09/13/17
FBCO
09/13/17
NO CHANGE
FBCO
Apple launch mostly as expected, says Credit Suisse
Credit Suisse analyst John Pitzer notes that Apple (AAPL) has announced four product updates largely in-line with expectations, and points out that semi companies in his coverage universe with exposure to Apple include Broadcom (AVGO), Micron (MU) and Texas Instruments (TXN).
SNAP Snap
$15.13

-0.14 (-0.92%)

08/31/17
08/31/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap (SNAP) initiated with a Neutral at Wedbush. 2. Momo (MOMO) initiated with a Buy at Goldman Sachs. 3. Safety, Income and Growth (SAFE) initiated with a Neutral at Mizuho. 4. Air Industries (AIRI) initiated with a Buy at Roth Capital. 5. Corcept Therapeutics (CORT) initiated with a Buy at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/11/17
DBAB
09/11/17
DOWNGRADE
Target $17
DBAB
Hold
Snap downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Lloyd Walmsley downgraded Snap to Hold and cut his price target for the shares to $17 from $20. The camera company closed Friday up 20c to $15.34. The risk/reward is more balanced with the shares up 29% since August 11, Walmsley tells investors in a research note. The analyst believes new products may take longer to improve the daily active user trajectory and points out his conversations across the advertising ecosystem yielded "decidedly mixed" feedback for Snap over the past month. Walmsley, however, continues to see an attractive long-term opportunity for Snap citing its "product innovation and improving ad tech."
09/11/17
WELS
09/11/17
NO CHANGE
WELS
Facebook taking long-term view of video opportunity, says Wells Fargo
Wells Fargo analyst Peter Stabler notes that Facebook (FB) is reportedly willing to spend as much as $1B to cultivate original video programming through 2018. The analyst believes that the scale of potential investment and particular investment targets suggest that Facebook is taking a long-term view of the video opportunity and that investments are likely to "significantly outstrip" near-term video monetization. Additionally, the company appears determined to drive Stories adoption in core Facebook to head off the threat of competitive incursion by Snap (SNAP), while expanding the distribution of advertising stories being widely adopted by marketers on Instagram.
09/11/17
09/11/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Snap (SNAP) downgraded to Hold from Buy at Deutsche Bank with analyst Lloyd Walmsley saying the risk/reward is more balanced with the shares up 29% since August 11. 2. Owens Corning (OC) downgraded to Neutral from Buy at Nomura Instinet with analyst Michael Wood saying high expectations create a balanced risk/reward at current share levels. 3. Kroger (KR) downgraded to Hold from Buy at Deutsche Bank with analyst Shane Higgins saying the company's sales and earnings growth for the next few years are likely to be below historical averages as it enters a period of increased investment, which warrants a lower multiple. 4. Sony (SNE) downgraded to Neutral from Buy at Citi with analyst Kota Ezawa saying the shares, following the recent rally, are now around fair value. The analyst expects the company's earnings growth to slow. 5. Newell Brands (NWL) downgraded to Hold from Buy at Jefferies with analyst Kevin Grundy citing management's "recent cautionary commentary" on its outlook for the second half of 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TEVA Teva
$19.33

0.83 (4.49%)

09/12/17
WELS
09/12/17
NO CHANGE
WELS
Cooper Companies Paragard IUD deal not cheap but 'good fit,' says Wells Fargo
Wells Fargo analyst Larry Biegelsen notes that Cooper Companies (COO) announced that it will acquire Paragard IUD from Teva (TEVA) for $1.1B cash and expects the transaction to close by the end of CY17. The analyst believes that while deal is not cheap, it appears to be a "good strategic fit." Further, he sees the acquisition as accretive to margins but not sales growth.
09/12/17
STFL
09/12/17
NO CHANGE
Target $275
STFL
Buy
Cooper Companies price target raised to $275 after Paragard deal at Stifel
Stifel analyst Jonathan Block said Cooper Companies' (COO) agreement to buy Teva's (TEVA) Paragard intrauterine device for $1.1B is a good fit for Cooper's CSI franchise that helps it achieve greater scale and integration of this product "appears relatively straight forward." Paragard's favorable margin structure leads to significant accretion in year one, noted Block, who raised his price target on Cooper shares to $275 from $265 and keeps a Buy rating on the stock.
09/12/17
BARD
09/12/17
NO CHANGE
Target $273
BARD
Outperform
Cooper Companies weakness on M&A news a buying opportunity, says Baird
Baird analyst Jeff Johnson noted Cooper Companies (COO) announced an acquisition of the Paragard IUD from Teva (TEVA) to expand its women's health offering. The analyst likes the acquisition given its minimal integration risk and solid accretion. He remains a buyer of Cooper stock at current levels and would use any pullbacks tied to the announcement as a buying opportunity. Johnson reiterated his Outperform rating and raised his price target to $273 from $267 on Cooper Companies shares.
09/12/17
JPMS
09/12/17
NO CHANGE
Target $235
JPMS
Neutral
JPMorgan sees mixed reaction to Cooper's acquisition of Paragard
JPMorgan analyst Andrew Hanover expects Cooper Companies' (COO) agreement to purchase Teva Pharmaceuticals' (TEVA) Paragard Intrauterine Device to garner a mixed reaction from investors. It will be hard for the 7% of accretion in FY18 "to be enough," since the stock's 45% rally year-to-date is likely driven by investors focused on its consumer-focused CVI business, and this deal does not fit that thesis, Hanover tells investors in a research note. The analyst keeps a Neutral rating on Cooper with a $235 price target.
PFE Pfizer
$35.37

1.05 (3.06%)

08/23/17
RAJA
08/23/17
NO CHANGE
Target $36
RAJA
Strong Buy
Paratek takeover speculation 'seems plausible,' says Raymond James
After Bloomberg reported that Paratek Pharmaceuticals (PRTK) is exploring its strategic options, including a possible sale, after receiving takeover interest, Raymond James analyst Laura Chico said she sees omadacycline as a promising asset and sees a takeout as "certainly one plausible outcome." While its "probably premature to think about a takeout price," Chico said that a possible price could arguably fall in the high-$40 to low-$50 range, adding that Merck (MRK), Pfizer (PFE) and Allergan (AGN) would all be potential buyers. She keeps a Strong Buy rating and $36 price target on Paratek shares.
09/13/17
RHCO
09/13/17
NO CHANGE
RHCO
AbbVie data increases confidence in RA opportunity, says SunTrust
SunTrust analyst John Boris says that data on AbbVie's (ABBV) UPAD for rheumatoid arthritis shows that its efficacy "appears competitive" with that of Pfizer's (PFE) Xeljanz/XR. The analyst says that the data increases his confidence in AbbVie's opportunity in RA. He keeps a $95 price target and a Buy rating on the shares.
09/11/17
CANT
09/11/17
NO CHANGE
Target $32
CANT
Neutral
Epipen market likely unaffected by Pfizer warning letter, says Cantor
Cantor Fitzgerald analyst Louise Chen said Friday that she does not expect the FDA's warning letter to Pfizer (PFE) to result in any material change in the market for Mylan's (MYL) Epipen in the near term. In a research note titled "No Need To Go Into Shock Yet Over PFE Warning Letter For Epipen," Chen added that she thinks Pfizer will work with the FDA to get the warning letter resolved. This news could be positive for Impax Laboratories (IPXL), which has the capacity to supply 30% of the market, above its current mid-20% range market share, Chen contends. She has a Neutral rating on Mylan and Overweight rating on Impax.
08/30/17
JEFF
08/30/17
NO CHANGE
Target $89
JEFF
Buy
Eli Lilly can rally 5% on September data, says Jefferies
Jefferies analyst Jeffrey Holford sees upside of 3%-5% for Eli Lilly (LLY) shares if the MONARCH 3 data at ESMO on September 10 shows a differentiated efficacy profile. The analyst sees downside of 2%-4% if abemaciclib's hazard ratio is inferior to Pfizer's (PFE) Ibrance. Holford believes expectations are modest for abemaciclib and that shares of Lilly remain attractive over the mid-term. He has a Buy rating on the name with an $89 price target.
KO Coca-Cola
$46.72

0.2 (0.43%)

06/07/17
BMOC
06/07/17
DOWNGRADE
BMOC
Market Perform
Coca-Cola downgraded to Market Perform from Outperform at BMO Capital
06/07/17
BMOC
06/07/17
DOWNGRADE
BMOC
Market Perform
Coca-Cola downgraded on valuation at BMO Capital
As noted earlier, BMO Capital downgraded Coca-Cola to Market Perform from Outperform. Analyst Amit Sharma downgraded the stock based on valuation. Target remains $46.
06/07/17
06/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PepsiCo (PEP) and Coca-Cola (KO) were downgraded to Market Perform from Outperform at BMO Capital. 2. Rent-A-Center (RCII) downgraded to Sell from Hold at Loop Capital with analyst Anthony Chukumba saying the secular shift to "virtual" rent-to-own has impaired the value of the company's core U.S. business. 3. HD Supply (HDS) was downgraded to Neutral from Outperform at Baird and to Hold from Buy at Drexel Hamilton. 4. IMAX (IMAX) downgraded to Hold from Buy at Benchmark with analyst Mike Hickey saying he fears movie goers' enthusiasm for recliner installations has shifted share away from IMAX and he now worries that recent per screen average deterioration could "prove less than transitory." 5. Danaher (DHR) downgraded to Neutral from Buy at Janney Capital with analyst Paul Knight saying he sees the company having more work to do optimizing its portfolio. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/08/17
BMOC
09/08/17
NO CHANGE
BMOC
Coca-Cola unlikely to be crippled by Amazon, says BMO Capital
BMO Capital says that sales of Coca-Cola's (KO) core products probably won't drop significantly due to competition from private labels. These Coca-Cola products "have high brand equity and low private-label penetration," BMO explained. Moreover, the soft drink maker could actually benefit from increased sales of higher margin, smaller size products through Amazon (AMZN), the firm believes.
WDAY Workday
$106.98

-1.29 (-1.19%)

08/31/17
OPCO
08/31/17
NO CHANGE
Target $117
OPCO
Outperform
Workday price target raised to $117 from $110 at Oppenheimer
Oppenheimer analyst Brian Schwartz raised his price target for Workday to $117 from $110 saying its business momentum appears strong across the Q2 reported results. The analyst believes the company has attractive long-term prospects, and remains bullish on the fundamentals. He reiterates an Outperform rating on the shares.
08/31/17
ADAM
08/31/17
NO CHANGE
Target $125
ADAM
Buy
Workday price target raised to $125 from $115 at Canaccord
Canaccord analyst Richard Davis raised his price target on Workday to $125 from $115 following solid Q2 results. The analyst said the report confirmed his checks the company was executing well and he believes there is upside to consensus revenue growth of 25% for 2018. He believes shares will move higher ahead of its October analyst day and into year-end and thus would be an aggressive buyer on any dips. Davis reiterated his Buy rating on Workday shares.
08/31/17
UBSW
08/31/17
NO CHANGE
Target $121
UBSW
Buy
Workday price target raised to $121 from $115 at UBS
UBS analyst Ian Strgar raised his price target on Workday to $121 from $115 following better than expected Q2 results. The analyst cited its broad based strength and raised guidance and believes its upcoming analyst day in October will serve as a catalyst. Strgar reiterated his Buy rating in Workday shares.
08/31/17
FBCO
08/31/17
NO CHANGE
Target $100
FBCO
Neutral
Workday price target raised to $100 from $94 at Credit Suisse
Credit Suisse analyst Michael Nemeroff raised his price target for Workday to $100 from $94 after the company reported "good" Q2 results with revenue, cash flows, and EPS above Street. The analyst reiterates a Neutral rating on the shares.
STZ Constellation Brands, also tag STZ.B
$204.62

0.92 (0.45%)

06/30/17
SUSQ
06/30/17
NO CHANGE
Target $169
SUSQ
Neutral
Constellation Brands rally should not be chased, says Susquehanna
Susquehanna analyst Pablo Zuanic noted Constellation Brands posted solid Q1 results and acknowledged the stock is a consensus buy. Despite the results, he said he would not chase the rally and he expects the stock will give back some of its gains in the quarter ahead. Zuanic raised his price target to $169 from $162 on Constellation Brands shares, but maintained his Neutral rating.
07/24/17
07/24/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Goldman Sachs (GS) downgraded to Neutral from Buy at UBS with analyst Brennan Hawken saying the market seems to be pricing in an inflection in Goldman's trading revenue despite the recent weakness, suggesting a recovery is needed to justify 2018 consensus estimates. 2. Constellation Brands (STZ) downgraded to Neutral from Conviction Buy at Goldman Sachs. 3. Boston Beer (SAM) downgraded to Sell from Neutral at Goldman Sachs with analyst Judy Hong saying she sees further downside risk from weaker volumes and believes 2018 will be another year of volume decline and limited margin offset. 4. athenahealth (ATHN) downgraded to Underweight from Equal-Weight at First Analysis with analyst Frank Sparacino saying the valuation at current share levels is ahead of the underlying fundamentals in the short term. 5. PPG (PPG) was downgraded to Hold from Buy at SunTrust and to Neutral from Buy at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/24/17
GSCO
07/24/17
DOWNGRADE
GSCO
Neutral
Constellation Brands downgraded to Neutral from Conviction Buy at Goldman Sachs
Goldman analyst Judy Hong downgraded Constellation Brands to Neutral from Conviction Buy with a $210 price target, down from $212. The analyst's earnings estimates are still above consensus but said recent Mexican peso appreciation limits margin upside and results in a her trimming earnings estimates.
06/30/17
GSCO
06/30/17
NO CHANGE
Target $212
GSCO
Conviction Buy
Constellation Brands price target raised to $212 from $198 at Goldman Sachs
Goldman analyst Judy Hong said Constellation Brands reported a Q1 beat driven by better than expected beer margins that reached 40%, 200bps above her estimate. The analyst expects beer margins to moderate somewhat in second half 2017 but said the beat was encouraging and further earnings upside is likely. Hong raised Constellation Brands' price target to $212 from $198 and reiterated her Conviction Buy rating.
AMTD TD Ameritrade
$44.25

0.54 (1.24%)

08/28/17
JEFF
08/28/17
NO CHANGE
Target $43
JEFF
Hold
TD Ameritrade fundamentals look good ahead of Scottrade deal, says Jefferies
After spending time with management, Jefferies analyst Daniel Fannon says TD Ameritrade's fundamentals look good ahead of the Scottrade transaction close. Ameritrade is seeing strong customer activity and solid net new asset growth trends, Fannon tells investors in a research note. He adds that the Scottrade deal is poised to close in the near term. The analyst keeps a Hold rating on TD Ameritrade with a $43 price target.
07/19/17
RHCO
07/19/17
NO CHANGE
RHCO
TD Ameritrade price target raised to $50 from $46 at SunTrust
SunTrust analyst Douglas Mewhirter increased his price target on TD Ameritrade as he says that the company reported "strong" Q3 results. He says that the company's "underappreciated institutional segment...should continue to thrive, and the pending Scottrade merger should generate considerable value." The analyst keeps a Buy rating on the stock.
07/13/17
07/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. HP Inc. (HPQ), 3D Systems (DDD), and Stratasys (SSYS) were initiated with a Neutral at Susquehanna. 2. Danaher (DHR) initiated with a Market Perform at Wells Fargo. 3. E-Trade (ETFC) and TD Ameritrade (AMTD) were initiated with a Buy at Rosenblatt, while Charles Schwab (SCHW) was initiated with a Neutral. 4. C&J Energy Services (CJ) initiated with a Buy at Jefferies. 5. BIO-key (BKYI) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/13/17
RSBL
07/13/17
INITIATION
Target $50
RSBL
Buy
TD Ameritrade initiated with a Buy at Rosenblatt
Rosenblatt analyst Chris Allen initiated TD Ameritrade with a Buy and a $50 price target saying the combination of the Scottrade acquisition, strong organic growth trends, and higher rates will result in best in class earnings over the next three years.

TODAY'S FREE FLY STORIES

AGN

Allergan

$215.00

-6.54 (-2.95%)

05:21
09/20/17
09/20
05:21
09/20/17
05:21
Recommendations
Allergan analyst commentary  »

Allergan pipeline largely…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

TRVG

trivago

$10.99

-0.11 (-0.99%)

05:15
09/20/17
09/20
05:15
09/20/17
05:15
Recommendations
trivago analyst commentary  »

trivago price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

05:12
09/20/17
09/20
05:12
09/20/17
05:12
Recommendations
Bed Bath & Beyond analyst commentary  »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRN

Acceleron

$38.97

-0.41 (-1.04%)

05:10
09/20/17
09/20
05:10
09/20/17
05:10
Recommendations
Acceleron analyst commentary  »

Acceleron price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

ICPT

Intercept

$96.20

0.45 (0.47%)

05:01
09/20/17
09/20
05:01
09/20/17
05:01
Recommendations
Intercept analyst commentary  »

Intercept recent pullback…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YAHOY

Yahoo Japan

$9.02

-0.03 (-0.33%)

04:57
09/20/17
09/20
04:57
09/20/17
04:57
Downgrade
Yahoo Japan rating change  »

Yahoo Japan downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$19.25

1.4 (7.84%)

04:56
09/20/17
09/20
04:56
09/20/17
04:56
Initiation
Epizyme initiated  »

Epizyme initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

CSGP

CoStar Group

$280.60

3.97 (1.44%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
CoStar Group management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

YEXT

Yext

$12.99

-0.27 (-2.04%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Yext management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

FCFS

First Cash Financial

$60.65

0.65 (1.08%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
First Cash Financial management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 22

    Sep

VNRX

VolitionRx

$2.75

0.07 (2.61%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
VolitionRx management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Citigroup to hold a conference »

2017 SMID and Travel…

SRCL

Stericycle

$70.19

-0.81 (-1.14%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Stericycle management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 27

    Sep

FIVN

Five9

$22.17

0.31 (1.42%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Five9 management to meet with Roth Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 25

    Sep

GMS

GMS Inc.

$33.50

-0.38 (-1.12%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
GMS Inc. management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

HRTG

Heritage Insurance

$11.83

-0.72 (-5.74%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Heritage Insurance management to meet with Sandler O'Neill »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

HZNP

Horizon Pharma

$12.10

0.26 (2.20%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Horizon Pharma management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

OHI

Omega Healthcare

$32.53

-0.12 (-0.37%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Omega Healthcare management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MZDAF

Mazda

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Mazda management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

SFS

Smart & Final Stores

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Smart & Final Stores management to meet with Loop Capital »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

SRCI

SRC Energy

$8.18

0.16 (2.00%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
SRC Energy management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 25

    Sep

  • 16

    May

AITB

AIT Therapeutics

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
AIT Therapeutics management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 26

    Sep

ARLP

Alliance Resource Partners

$18.90

-0.05 (-0.26%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Alliance Resource Partners management to meet with MKM Partners »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

EMR

Emerson

$63.21

0.22 (0.35%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Emerson management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

SCSC

Scansource

$40.70

-0.05 (-0.12%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Scansource management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.